-The Economic Times CHANDIGARH: Haryana government today transferred whistleblower in Robert Vadra-DLF land deal, Ashok Khemka, Haryana IAS officer to department of Archives within six months of his recent posting as managing director of Haryana Seeds Development Corporation. The latest transfer of Khemka, second in last few months and 44th in all, is seen as a bid to avoid further threat to IMAge of the Congress government that has taken beating after...
More »SEARCH RESULT
Total Matching Records found : 2545
A question of standards, not principle-Vinay Sitapati
-The Indian Express India is no insecure dictatorship junking international obligations for cheap populism. The highest court of the world's largest democracy has made a nuanced distinction between real innovation and marketing gimmickry. Yet, the Swiss pharmaceutical giant Novartis's response to the recent Supreme Court verdict in Novartis vs Union of India has been imperial in tone. The judgment "discourages innovative drug discovery", it claimed. It accused Indian law of lagging...
More »Calling big pharma’s bluff -Dwijen Rangnekar
-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...
More »Domestic firms rejoicing on Glivec verdict-Sushmi Dey
-The Business Standard Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug IMAtinib mesylate or Glivec, as sold by the Swiss drug maker. This is because the judgement...
More »YK Sapru, founder chairperson of Cancer Patients Aid Association (CPAA) interviewed by Sushmi Dey
-The Business Standard Interview with Founder chairman of Cancer Patients Aid Association Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients....
More »
